News — Samus Therapeutics

News

Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing the Company’s Platform for Treating Neurodegenerative Diseases

July 29, 2020

Samus Therapeutics to Present at BIO CEO & Investor Conference

February 4, 2020

Study Published in Nature Communications Highlights the Role of the Epichaperome in Protein Connectivity-based Dysfunction in Alzheimer’s Disease

February 4, 2020

Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71 with Ruxolitinib in Myelofibrosis at the ASH 2019 Annual Meeting

December 9, 2019

Samus Therapeutics Announces Presentation of PU-AD Phase 1 Data for Alzheimer’s Disease at CTAD Congress

December 5, 2019

Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer’s Disease

July 23, 2019

Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis

June 13, 2018

Samus Therapeutics Announces Launch of Expanded Clinical Development Programs for Novel Anti-Epichaperome Small Molecules to Diagnose and Treat Cancer and Neurodegenerative Disease

March 30, 2017